Proving Of Bacopa Monniera (BRAHMI)

Background:Brahmi has been used by Ayurvedic medical practitioners in India for almost 3000 years. The earliest chronicled mention is in the Ayurvedic treatise, the Charaka Samhita (100 A.D.), in which Brahmi is recommended in formulations for the management of a range of mental conditions including anxiety, poor cognition and lack of concentration. According to the Charaka, Brahmi acts as an effective braintonic that boostsone's capabilities to think and reason. The Sushruta Samhita 6 (200 A.D.) attributes the plant with efficacy in maintaining acuity of intellect and memory. The Bhavprakasha Nighantu, commonly known as the Indian Materia Medica (1500 A.D.),cites the plant as a brain tonic that is effective in maintaining vigor and intellect. Material And Methods:Method for the study has been selected as placebo controlled “Double Blind Method”.Result:In drug proving out of seventeen provers sixteen manifested the symptoms consequent upon the administration of drug. There is a drop of one prover due to death of near one on the 5thday of phase-I. One prover got the typhoid fever so he was continued on abstinence of medicine because of the symptoms persisted till the completion of phase-II.Conclusion:This drug is initially use d clinically in mother tincture form and not proved completely on the principles laid down in Organon of medicine. I have taken this drug to prove it in 30c & 200c potency. For the study placebo control “Double blind method” is been selected.

An open-label, exploratory documentation of proving-symptoms of CVN01 (Coronavirus nosode from the clinical sample) in healthy volunteers

Homeopathic Pathogenetic Trials (Proving) are human studies to examine the pathogenetic effects of investigational drugs in high dilution on healthy volunteers. As a part of the new coronavirus nosode development process for prophylactic use, the phase 1 study was conducted. The documentation of proving symptoms for a fast-track nosode development for a pandemic condition was the objectives of this study. An open-label trial to evaluate the safety and proving symptoms of Coronavirus nosode given orally to 10 volunteers (18-65 years age and of both the genders). Volunteers were administered 6 doses of nosode as 6 pills twice daily for 3 consecutive days. Pre and post examinations (physical), vital signs, and laboratory investigations, were done at day 0, 17, 34. Symptoms experienced by the volunteers were recorded. RESULTS Symptoms reported by volunteers were analyzed. The symptoms reported were mild to severe but reversible and matching with the symptoms produced by the viral infection. There were no serious/fatal adverse events during the study. The basic biochemistry and Liver Function tests were not affected by the Nosode. New nosode developed during a pandemic condition produced certain symptoms in the homeopathic pathogenetic trial as a part of the Phase 1 study.